Literature DB >> 16740991

Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice.

Rhoda E Kuc1, Janet J Maguire, Anthony P Davenport.   

Abstract

We have previously shown that in homozygous endothelin (ET)(B)-/- deficient mice, ET(A) receptor density is significantly downregulated in the brain by 45%. In these mice, plasma ET-1 levels are elevated. Our aim was to use quantitative autoradiography to establish the distribution of ET receptor subtypes in peripheral tissues from wild-type mice and to measure the density of the ET(A) subtype in ET(B)-/- knockout animals. Our second aim was to test whether deletion of ET(B) receptors, which is associated with elevated plasma levels of ET-1, would also reduce ET(A) expression in the periphery. In longitudinal sections from wild-type mice, the highest densities of ET(A) receptors localized to major organs including the ventricle of the heart, lung, and liver parenchyma. High densities of ET(A) receptors were detected in the smooth muscle layer of the vasculature such as intrarenal vessels as well as the smooth muscle layer and epithelial cells of the gastrointestinal tract. In these tissues, the ET(A) subtype was more abundant, representing between 60% and 100% of the ET receptors. ET(B) receptors predominated in the medulla of kidney, with high densities also localizing to glomeruli within the cortex and to the sinusoids from the liver. Lower densities of ET(B) receptors were also present in the lung, heart, liver, and the smooth muscle layer of the gastrointestinal tract. In ET(B)-/- knockout mice, ET(B) receptors were not detected as expected by either ligand binding or immunocytochemistry. The pattern of ET(A) receptor distribution in the ET(B)-/- knockout mice was similar to the controls, but the density of ET(A) receptors was significantly reduced in the lung by 39%. Diminished responses to the endogenous agonist after repeated stimulation are an important feature of G-protein signaling, preventing potential damage to the overstimulated cell, and it is likely that downregulation occurs in response to higher circulating levels of ET-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740991

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  11 in total

1.  Endothelin-1 receptor A blocker darusentan decreases hepatic changes and improves liver repopulation after cell transplantation in rats.

Authors:  Ralf Bahde; Sorabh Kapoor; Preeti Viswanathan; Hans-Ullrich Spiegel; Sanjeev Gupta
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

2.  Efficient Reconstitution of Hepatic Microvasculature by Endothelin Receptor Antagonism in Liver Sinusoidal Endothelial Cells.

Authors:  Neelam Yadav; Fadi Luc Jaber; Yogeshwar Sharma; Priya Gupta; Preeti Viswanathan; Sanjeev Gupta
Journal:  Hum Gene Ther       Date:  2018-12-18       Impact factor: 5.695

3.  Directly acting drugs prostacyclin or nitroglycerine and endothelin receptor blocker bosentan improve cell engraftment in rodent liver.

Authors:  Ralf Bahde; Sorabh Kapoor; Sriram Bandi; Kuldeep K Bhargava; Christopher J Palestro; Sanjeev Gupta
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

Review 4.  High-altitude adaptation in humans: from genomics to integrative physiology.

Authors:  Priti Azad; Tsering Stobdan; Dan Zhou; Iain Hartley; Ali Akbari; Vineet Bafna; Gabriel G Haddad
Journal:  J Mol Med (Berl)       Date:  2017-09-26       Impact factor: 4.599

5.  Endothelin receptor B, a candidate gene from human studies at high altitude, improves cardiac tolerance to hypoxia in genetically engineered heterozygote mice.

Authors:  Tsering Stobdan; Dan Zhou; Eilleen Ao-Ieong; Daniel Ortiz; Roy Ronen; Iain Hartley; Zhuohui Gan; Andrew D McCulloch; Vineet Bafna; Pedro Cabrales; Gabriel G Haddad
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

6.  Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats.

Authors:  Junlan Zhang; Yiqun Ling; Liping Tang; Bao Luo; David M Pollock; Michael B Fallon
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02-05       Impact factor: 4.052

7.  Cardiac-specific knockout and pharmacological inhibition of Endothelin receptor type B lead to cardiac resistance to extreme hypoxia.

Authors:  Tsering Stobdan; Dan Zhou; Alexander T Williams; Pedro Cabrales; Gabriel G Haddad
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

8.  Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.

Authors:  Mark Southwood; Robert V MacKenzie Ross; Rhoda E Kuc; Guy Hagan; Karen K Sheares; David P Jenkins; Martin Goddard; Anthony P Davenport; Joanna Pepke-Zaba
Journal:  Life Sci       Date:  2016-02-10       Impact factor: 5.037

Review 9.  Endothelin.

Authors:  Anthony P Davenport; Kelly A Hyndman; Neeraj Dhaun; Christopher Southan; Donald E Kohan; Jennifer S Pollock; David M Pollock; David J Webb; Janet J Maguire
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.

Authors:  Thomas J Ford; David Corcoran; Sandosh Padmanabhan; Alisha Aman; Paul Rocchiccioli; Richard Good; Margaret McEntegart; Janet J Maguire; Stuart Watkins; Hany Eteiba; Aadil Shaukat; Mitchell Lindsay; Keith Robertson; Stuart Hood; Ross McGeoch; Robert McDade; Eric Yii; Naveed Sattar; Li-Yueh Hsu; Andrew E Arai; Keith G Oldroyd; Rhian M Touyz; Anthony P Davenport; Colin Berry
Journal:  Eur Heart J       Date:  2020-09-07       Impact factor: 35.855

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.